Ex-As­traZeneca ex­ec Lisa An­son to lead do-over at Redx; Ad­vax­is shakes up C-suite

Redx $REDX has en­list­ed es­teemed British ex­ec Lisa An­son to lead the com­pa­ny’s do-over as its CEO. Hav­ing held man­age­ment roles at As­traZeneca for 20 years — serv­ing as As­traZeneca UK’s pres­i­dent for the last six — An­son, who’s al­so the pres­i­dent of the As­so­ci­a­tion of the British Phar­ma­ceu­ti­cal In­dus­try, in­spires con­fi­dence about turn­ing things around for the bat­tered biotech. If the hopes are high, so are the stakes. Redx saw its shares sus­pend­ed al­most a year ago af­ter the city of Liv­er­pool said it went delin­quent on a £2 mil­lion loan, and was hit by a safe­ty cri­sis just last month that forced it to halt a PhI/II tri­al. An­son, how­ev­er, is up­beat about the work cut out for her: “The team have im­pressed me and the com­pa­ny now has a clear fo­cus on some very ex­cit­ing ar­eas of sci­ence in both fi­bro­sis and can­cer where there are a num­ber of on­go­ing pro­grams.” When she comes on the job on June 1, ex­ec­u­tive chair­man Iain Ross will re­vert to a non-ex­ec­u­tive po­si­tion.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.